Results 171 to 180 of about 110,732 (262)

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort

Alimentary Pharmacology &Therapeutics, EarlyView.
In 1,756,593 young adults, a generalized boosted survival model predicted incident HCC with strong discrimination (1‐year AUROC 0.945; 5‐year 0.825). The 1‐year horizon uniquely targets an imaging‐silent, pre‐diagnosis window, showing routine clinical signals can flag otherwise undetectable risk.
Seogsong Jeong, Gi‐Ae Kim, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Keon Wook Kang, Hwamin Lee, Won Kim   +7 more
wiley   +1 more source

The aMAP score combined with plasma cfDNA methylation testing for risk stratification in hepatitis population: a case-control study. [PDF]

Sci Rep
Chen D, Zhang K, Lv T, Jian X, Zhang J, An Y, Ren D, Long F, Liu S.   +8 more
europepmc   +1 more source

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care

Alimentary Pharmacology &Therapeutics, EarlyView.
This cross‐sectional study of 84 general practices found 24.3% had At‐Risk MASH defined by FNI > 0.30, and 4.3% had advanced fibrosis defined by FIB‐4 > 2.67. Diabetes and socio‐economic disadvantage were strong predictors of significant liver disease.
Leon A. Adams, Shaoke Lei, Luis Calzadilla‐Bertot, Silja Schrader, Sophie Frear, Chian Zhou, Sarah E. Heywood, Jon Emery   +7 more
wiley   +1 more source

Herbal remedies for hepatic diseases: A review of medicinal herbs in the treatment of liver disorders. [PDF]

Chin Herb Med
Saraswat I, Goel A, Gupta J.
europepmc   +1 more source

Socioeconomic Inequalities in Receipt of Curative‐Intent Treatment and Survival After Surveillance‐Detected Hepatocellular Carcinoma: A Nationwide Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Socioeconomic inequalities in receipt of curative‐intent treatment and survival persist among individuals with surveillance‐detected HCC within a universal healthcare system. These findings suggest that surveillance alone is insufficient to ensure equitable outcomes and highlight the need for strategies addressing social determinants across the care ...
Hannes Hagström, Jeffrey V. Lazarus, Malin Sternby Eilard, Adam Bergman, Magnus Rizell, Per Sandström, Juan Vaz   +6 more
wiley   +1 more source

Prognostic associations of vitamin D deficiency with disease severity, survival, and complications in alcohol-related liver disease. [PDF]

Front Med (Lausanne)
He Q, Duan F, Mao C, Cheng J, Wang Y, Zeng Y, Yang S.   +6 more
europepmc   +1 more source

S1 Guideline on Infected Interdigital Intertrigo (also called Gram‐Negative Toe Web Infection)

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Infected interdigital intertrigo is an exudative, macerating, mixed infection of the toe webs in which gram‐negative bacteria (Pseudomonas aeruginosa and Enterobacterales) seem prevalent, but in which gram‐positive pathogens (Staphylococcus [S.] aureus, streptococci, enterococci) and fungi (dermatophytes, yeasts) also occur.
Christoph Zeyen, Dietrich Abeck, Karsten Becker, Joachim Dissemond, Birgit Kahle, Hans Peter Lorenzen, Bettina Löffler, Andreas Maier‐Hasselmann, Till Mittank‐Weidner, Alexander Nast, Cord Sunderkötter   +10 more
wiley   +1 more source

Pregnancy in Liver Cirrhosis: A Rare Clinical Case and Review of Current Management Strategies. [PDF]

J Clin Med
Stoyanova N, Yordanov A, Nikolov A, Gorcheva Z, Popovski N.   +4 more
europepmc   +1 more source

Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). Methods Patients with MASLD and T2D who had MBS or semaglutide in 2018–2023 were identified (TriNetX database).
Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson   +5 more
wiley   +1 more source